References

1. Alessandra Saldanha De Mattos Matheus; Lucianne Righeti Monteiro Tannus; Roberta Arnoldi Cobas; Catia C. Sousa Palma; Carlos Antonio Negrato; Marilia De Brito Gomes; Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension 2013, 2013, 653789, 10.1155/2013/653789.
2. Fonseca, V.; Desouza, C.; Asnani, S.; Jialal, I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr. Rev. 2004, 25, 153–175.
3. Vesa, C.M.; Popa, A.R.; Bungau, S.; Daina, L.G.; Buhas, C.; Judea-Pusta, C.T.; Pasca, B.; Dimulescu (Nica), I.A.; Zaha, D.C. Exploration of insulin sensitivity, insulin resistance, early insulin secretion and β-cell function, and their relationship with glycated hemoglobin level in normal weight patients with newly diagnosed type 2 diabetes mellitus. Rev. Chim. 2019, 70, 4217–4223.
4. Jay S. Skyler; Richard Bergenstal; Robert O. Bonow; John B. Buse; Prakash Deedwania; Edwin A.M. Gale; Barbara V. Howard; M. S. Kirkman; Mikhail Kosiborod; Peter Reaven; et al.Robert S. Sherwin Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care 2008, 32, 187-192, 10.2337/dc08-9026.
5. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group; Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; et al.et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358, 2545–2559.
6. Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; et al.Pavel HametStephen B. HarrapS. R. HellerLisheng LiuGiuseppe ManciaCarl Erik MogensenChangyu PanNeil R PoulterAnthony RodgersBryan WilliamsSeverine BompointBastiaan E. De GalanRohina JoshiFlorence Travert Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2008, 358, 2560-2572, 10.1056/NEJMoa0802987.
7. Nathan, D.M.; Cleary, P.A.; Backlund, J.Y.; Genuth, S.M.; Lachin, J.M.; Orchard, T.J.; Raskin, P.; Zinman, B.; Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353, 2643–2653.
8. Rury R. Holman; Sanjoy Paul; Mary Angelyn Bethel; David R. Matthews; H. Andrew W. Neil; 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 2008, 359, 1577-1589, 10.1056/NEJMoa0806470.
9. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 2017, 40 (Suppl. S1), S1–S2.
10. Bernard Zinman; John M. Lachin; Silvio E. Inzucchi; Pantelis Sarafidis; Apostolos Tsapas; Michael Fischereder; Ulf Schönermarck; Jonathan L Edwards; Robert Rosenstein; Augustus Hough; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.. New England Journal of Medicine 2015, 373, 2117–2128, 10.1056/NEJMc1600827.
11. Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. for the CANVAS Program Collaborative Group.; et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017, 377, 644–657.
12. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; et al.et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016, 375, 311–322.
13. Lorber, D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 2014, 7, 169–183.
14. American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care 2018, 41 (Suppl. S1), S3.
15. Wang, Y.W.; He, S.J.; Feng, X.; Cheng, J.; Luo, Y.T.; Tian, L.; Huang, Q. Metformin: A review of its potential indications. Drug. Des. Devel. Ther. 2017, 11, 2421–2429.
16. Manuela Stoicescu; C Csepento; Gabriela Muţiu; Simona Bungau; The role of increased plasmatic renin level in the pathogenesis of arterial hypertension in young adults.. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2011, 52, 419–423.
17. Ian H. De Boer; Sripal Bangalore; Athanase Benetos; Andrew M. Davis; Erin D Michos; Paul Muntner; Peter Rossing; Sophia Zoungas; George Bakris; Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care 2017, 40, 1273-1284, 10.2337/dci17-0026.
18. Thomopoulos, C.; Parati, G.; Zanchetti, A.; Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10—Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J. Hypertens. 2014, 32, 2285–2295.
19. Liang Chen; Jian-Hao Pei; Jian Kuang; Hong-Mei Chen; Zhong Chen; Zhong-Wen Li; Hua-Zhang Yang; Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. Metabolism 2015, 64, 338-347, 10.1016/j.metabol.2014.10.018.
20. Bruno Vergès; Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundamental and Clinical Pharmacology 2009, 23, 681-685, 10.1111/j.1472-8206.2009.00739.x.
21. Colhoun, H.M.; Betteridge, D.J.; Durrington, P.N.; Hitman, G.A.; Neil, H.A.; Livingstone, S.J.; Thomason, M.J.; Mackness, M.I.; Charlton-Menys, V.; Fuller, J.H.; et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004, 364, 685–696.
22. Bruno Vergès; Pathophysiology of diabetic dyslipidaemia: where are we?. Diabetologia 2015, 58, 886-899, 10.1007/s00125-015-3525-8.
23. Cholesterol Treatment Trialists' (Ctt) Collaborators; Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 2008, 371, 1670–1681, 10.1016/s0140-6736(08)60104-x.
24. ACCORD Study Group; Ginsberg, H.N.; Elam, M.B.; Lovato, L.C.; Crouse, J.R.; Leiter, L.A.; Linz, P.; Friedewald, W.T.; Buse, J.B.; Gerstein, H.C.; et al.et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 2010, 362, 1563–1567, 10.1056/nejmx100016.
25. Keech, A.; Simes, R.J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M.R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; et al.et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366, 1849–1861.
26. Scott, R.; O’Brien, R.; Fulcher, G.; Pardy, C.; D’Emden, M.; Tse, D.; Taskinen, M.R.; Ehnholm, C.; Keech, A.; Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32, 493–498.
27. Protasio Lemos Da Luz; Desiderio Favarato; Jose Rocha Faria-Neto; Pedro Lemos; Antonio Carlos Palandri Chagas; High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008, 63, 427–432.
28. Nanik Ram; Bilal Ahmed; Fauzan Hashmi; Abdul Jabbar; Importance of measuring non-HDL cholesterol in type 2 diabetes patients.. Journal of the Pakistan Medical Association 2014, 64, 124–128.
29. Emerging Risk Factors Collaboration; Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; et al.Chris J PackardRory CollinsSimon G ThompsonJohn DaneshThe Emerging Risk Factors Collaboration* Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA 2009, 302, 1993-2000, 10.1001/jama.2009.1619.
30. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al.et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188.
31. Klaus G Parhofer; Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology 2011, 6, 401-411, 10.2217/clp.11.32.
32. Jian Liu; Christopher Sempos; Richard P. Donahue; Joan Dorn; Maurizio Trevisan; Scott M. Grundy; Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes.. Diabetes Care 2005, 28, 1916-1921, 10.2337/diacare.28.8.1916.
33. Robinson, J.G.; Wang, S.; Smith, B.J.; Jacobson, T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 2009, 53, 316–322.
34. Frontini, M.G.; Srinivasan, S.R.; Xu, J.; Tang, R.; Bond, M.G.; Berenson, G.S. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics 2008, 121, 924–929.
35. Saeed Ghodsi; Alipasha Meysamie; Mehrshad Abbasi; Reza Ghalehtaki; Alireza Esteghamati; Masoud M. Malekzadeh; Fereshteh Asgari; Mohammad M. Gouya; Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults.. Journal of Diabetes & Metabolic Disorders 2017, 16, 25, 10.1186/s40200-017-0306-6.
36. Marie Russell; Angela Silverman; Jerome L. Fleg; Elisa T. Lee; Mihriye Mete; Matthew Weir; Charlton Wilson; Fawn Yeh; Barbara V. Howard; Wm. James Howard; et al. Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study. Journal of Clinical Lipidology 2010, 4, 435-443, 10.1016/j.jacl.2010.07.007.
37. Gloria Lena Vega; Scott M. Grundy; Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease.. Journal of Clinical Lipidology 2019, 13, 563-567, 10.1016/j.jacl.2019.05.012.
38. Usui, T.; Nagata, M.; Hata, J.; Mukai, N.; Hirakawa, Y.; Yoshida, D.; Kishimoto, H.; Kitazono, T.; Kiyohara, Y.; Ninomiya, T. Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: The Hisayama Study. J. Atheroscler. Thromb. 2017, 24, 706–715.
39. Moisi, M.I.; Rus, M.; Bungau, S.; Zaha, C.D.; Uivarosan, D.; Fratila, O.; Tit, D.M.; Endres, L.; Nistor-Cseppento, D.C.; Popescu, M.I. Acute coronary syndromes in chronic kidney disease: Clinical and therapeutic characteristics. Medicina 2020, 56, 118.
40. Viktor Hanak; Julian Munoz; Joe Teague; Alfred Stanley; Vera Bittner; Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. The American Journal of Cardiology 2004, 94, 219-222, 10.1016/j.amjcard.2004.03.069.
41. R M Conroy; Kalevi Pyörälä; A P Fitzgerald; S Sans; A Menotti; G. De Backer; Dirk De Bacquer; P Ducimetière; P Jousilahti; U Keil; et al.I NjølstadR G OganovT ThomsenH Tunstall-PedoeA TverdalH WedelP WhincupLars WilhelmsenI.M. Graham Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003, 24, 987–1003.
42. Kazuya Fujihara; Hiroaki Suzuki; Akira Sato; Tomoko Ishizu; Satoru Kodama; Yoriko Heianza; Kazumi Saito; Hitoshi Iwasaki; Kazuto Kobayashi; Shigeru Yatoh; et al.Akimitsu TakahashiNaoya YahagiHirohito SoneHitoshi Shimano Comparison of the Framingham Risk Score, UK Prospective Diabetes Study (UKPDS) Risk Engine, Japanese Atherosclerosis Longitudinal Study-Existing Cohorts Combine (JALS-ECC) and Maximum Carotid Intima-Media Thickness for Predicting Coronary Artery Stenosis in Patients with Asymptomatic Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis 2014, 21, 799-815, 10.5551/jat.20487.
43. Ittaman, S.V.; VanWormer, J.J.; Rezkalla, S.H.; The role of aspirin in the prevention of cardiovascular disease. Clin. Med. Res. 2014, 12, 147–154.
44. Simmons, R.K.; Coleman, R.L.; Price, H.C.; Holman, R.R.; Khaw, K.T.; Wareham, N.J.; Griffin, S.J.; Performance of the UK prospective diabetes study risk engi ne and the framingham risk equations in estimating cardiovascular disease in the EPIC- Norfolk Cohort. Diabetes Care 2009, 32, 708–713.
45. Guzder, R.N.; Gatling, W.; Mullee, M.A.; Mehta, R.L.; Byrne, C.D. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study. Diabetes Med. 2005, 22, 554–562.
46. Echouffo-Tcheugui, J.B.; Kengne, A.P. Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. Diabetes Metab. 2013, 39, 389–396.
47. James Black; Stephen J Sharp; Nicholas J Wareham; Annelli Sandbæk; Guy E H M Rutten; Torsten Lauritzen; Kamlesh Khunti; Michael J. Davies; Knut Borch-Johnsen; S. J. Griffin; et al.Rebecca Simmons Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial.. British Journal of General Practice 2014, 64, e208-e216, 10.3399/bjgp14X677833.
48. Maria Manea; Dragos Marcu; Anca Pantea Stoian; Mihnea Alexandru Gaman; Amelia Maria Gaman; Bogdan Socea; Tiberiu Paul Neagu; Ana Maria Alexandra Stanescu; Ovidiu Gabriel Bratu; Camelia Cristina Diaconu; et al. Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation A review. Revista de Chimie 2018, 69, 3280-3284, 10.37358/rc.18.11.6730.
49. Dipika Bansal; Ramya S. R. Nayakallu; Kapil Gudala; Rajavikram Vyamasuni; Anil Bhansali; Agreement between Framingham Risk Score and United Kingdom Prospective Diabetes Study Risk Engine in Identifying High Coronary Heart Disease Risk in North Indian Population. Diabetes & Metabolism Journal 2015, 39, 321-327, 10.4093/dmj.2015.39.4.321.
50. John Kao; Jonathan Tobis; Robyn L McClelland; Melissa R Heaton; Barry R Davis; David R Holmes; Jesse W Currier; Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. The American Journal of Cardiology 2004, 93, 1347-1350, 10.1016/j.amjcard.2004.02.028.
51. Hauner, H.; Managing type 2 diabetes mellitus in patients with obesity. Treat Endocrinol. 2004, 3, 223–232.
52. Saisho, Y. Metformin and Inflammation: Its potential beyond glucose-lowering effect. Endocr. Metab. Immune Disord. Drug Targets 2015, 15, 196–205.
53. Popa, A.R.; Bungau, S.; Vesa, C.M.; Bondar, A.C.; Pantis, C.; Maghiar, O.; Dimulescu (Nica), I.A.; Nistor-Cseppento, D.C.; Rus, M. Evaluating the efficacy of the treatment with benfotiamine and alpha-lipoic acid in distal symmetric painful diabetic polyneuropathy. Rev. Chim. 2019, 70, 3108–3114.
54. Chakraborty, A.; Chowdhury, S.; Bhattacharyya, M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 2011, 93, 56–62.
55. Abdel-Daim, M.M.; El-Tawil, O.S.; Bungau, S.G.; Atanasov, A.G. Applications of antioxidants in metabolic disorders and degenerative diseases: Mechanistic approach. Oxid. Med. Cell. Longev. 2019, 2019.
56. Landin-Wilhelmsen, K. Metformin and blood pressure. J. Clin. Pharm. Ther. 1992, 17, 75–79.
57. Gaman, M.A.; Dobrica, E.C.; Pascu, E.G.; Cozma, M.A.; Epingeac, M.E.; Gaman, A.M.; Pantea Stoian, A.; Bratu, O.G.; Diaconu, C.C. Cardiometabolic risk factors for atrial fibrillation in type 2 diabetes mellitus: Focus on hypertension, metabolic syndrome and obesity. J. Mind Med. Sci. 2019, 6, 157–161.
58. Wendy L. Bennett; Nisa M. Maruthur; Sonal Singh; Jodi B. Segal; Lisa M. Wilson; Ranee Chatterjee; Spyridon S. Marinopoulos; Milo A. Puhan; Padmini Ranasinghe; Lauren Block; et al.Wanda K. NicholsonSusan HutflessEric B. BassShari Bolen Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.. Annals of Internal Medicine 2011, 154, 602-613, 10.7326/0003-4819-154-9-201105030-00336.
59. Daniel S. Hsia; Owen Grove; William T. Cefalu; An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.. Current Opinion in Endocrinology & Diabetes and Obesity 2017, 24, 73-79, 10.1097/MED.0000000000000311.
60. Pereira, M.J.; Eriksson, J.W. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019, 79, 219–230.
61. Davidson, J.A. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: Overview of current evidence. Postgrad. Med. 2019, 131, 251–260.
62. Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi; Diabetic Nephropathy and CKD—Analysis of Individual Patient Serum Creatinine Trajectories: A Forgotten Diagnostic Methodology for Diabetic CKD Prognostication and Prediction. Journal of Clinical Medicine 2015, 4, 1348-1368, 10.3390/jcm4071348.
63. Natalia De Albuquerque Rocha; Ian J Neeland; Peter A McCullough; Robert D Toto; Darren K McGuire; Effects of sodium glucose co-transporter 2 inhibitors on the kidney.. Diabetes and Vascular Disease Research 2018, 15, 375-386, 10.1177/1479164118783756.
64. Heidi Storgaard; Lise Lotte Gluud; Cathy Bennett; Magnus F. Grøndahl; Mikkel B. Christensen; Filip K. Knop; Tina Vilsbøll; Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLOS ONE 2016, 11, e0166125, 10.1371/journal.pone.0166125.
65. Nigro, J.; Osman, N.; Dart, A.M.; Little, P.J.; Insulin Resistance and Atherosclerosis. Endocr. Rev. 2006, 27, 242–259.
66. Garber, A.J.; Abrahamson, M.J.; Barzilay, J.I.; Blonde, L.; Bloomgarden, Z.T.; Bush, M.A.; Dagogo-Jack, S.; DeFronzo, R.A.; Einhorn, D.; Fonseca, V.A.; et al.et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocr. Pract. 2018, 24, 91–120.
67. Del Olmo-Garcia, M.I.; Merino-Torres, J.F.; GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J. Diabetes Res. 2018, 2018, 4020492.
68. Lalita Prasad-Reddy; Diana Isaacs; A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in Context 2015, 4, 212283, 10.7573/dic.212283.
69. John B. Buse; Daniel J. Drucker; Kristin L. Taylor; Terri Kim; Brandon Walsh; Hao Hu; Ken Wilhelm; Michael Trautmann; Larry Z. Shen; Lisa E. Porter; et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care 2010, 33, 1255-1261, 10.2337/dc09-1914.
70. Buse, J.B.; Rosenstock, J.; Sesti, G.; Schmidt, W.E.; Montanya, E.; Brett, J.H.; Zychma, M.; Blonde, L.; LEAD-6 Study Group.; Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374, 39–47.
71. Sun, F.; Wu, S.; Guo, S.; Yu, K.; Yang, Z.; Li, L.; Zhang, Y.; Quan, X.; Ji, L.; Zhan, S. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res. Clin. Pract. 2015, 110, 26–37.
72. Okerson, T.; Yan, P.; Stonehouse, A.; Brodows, R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am. J. Hypertens. 2010, 23, 334–339.
73. Feng Sun; Shanshan Wu; Jing Wang; Shuxia Guo; Sanbao Chai; Zhirong Yang; Lishi Li; Yuan Zhang; Linong Ji; Siyan Zhan; et al. Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics 2015, 37, 225-241.e8, 10.1016/j.clinthera.2014.11.008.
74. David C. Klonoff; John B. Buse; Loretta L. Nielsen; Xuesong Guan; Christopher L. Bowlus; John H. Holcombe; Matthew E. Wintle; D. G. Maggs; Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008, 24, 275-286, 10.1185/030079907x253870.
75. Guillermo Umpierrez; Linda Shurzinske; Pechtner V; Santiago Tofé Povedano; Federico Pérez Manghi; Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care 2014, 37, 2168-2176, 10.2337/dc13-2759.
76. Tracey Gaspari; HongBin Liu; Iresha Welungoda; Yunshan Hu; Robert E. Widdop; Lotte Bjerre Knudsen; Richard W Simpson; Anthony E. Dear; A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diabetes and Vascular Disease Research 2011, 8, 117-124, 10.1177/1479164111404257.
77. Yun Xie; Shao-Xin Wang; Wei-Wei Sha; Xue Zhou; Wei-Lin Wang; Li-Pin Han; Dai-Qing Li; De-Min Yu; Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chinese Medical Journal 2008, 121, 2134-2138, 10.1097/00029330-200811010-00005.
78. Ming Yu; Carol Moreno; Kimberly M Hoagland; Annette Dahly; Katie Ditter; Mahesh Mistry; R J Roman; Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. Journal of Hypertension 2003, 21, 1125-1135, 10.1097/00004872-200306000-00012.
79. Saraiva, F.K.; Sposito, A.C.; Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc. Diabetol. 2014, 13, 142.
80. Steven P Marso; Steve C Bain; Agostino Consoli; Freddy G. Eliaschewitz; Esteban Jódar; Lawrence A. Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L. Warren; et al.Vincent WooOluf HansenAnders G. HolstJonas PetterssonTina VilsbøllSUSTAIN-6 Investigators Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. New England Journal of Medicine 2016, 375, 1834-1844, 10.1056/NEJMoa1607141.
81. Bertoccini, L.; Baroni, M.G. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Adv. Exp. Med. Biol. 2020.
82. Moisi, M.; Vesa, C.M.; Bungau, S.; Tit, D.M.; Corb Aron, R.A.; Bratu, O.; Diaconu, C.C.; Rus, M.; Popescu, M.I.; Acute kidney injury incidence and models for mortality prediction in acute coronary syndromes. Rom. J. Mil. Med. 2020, 123, 133–140.
83. Vicky Cheng; Sangeeta R. Kashyap; Weight Considerations in Pharmacotherapy for Type 2 Diabetes. Journal of Obesity 2010, 2011, 984245, 10.1155/2011/984245.
84. Markolf Hanefeld; Brian M. Frier; Frank Pistrosch; Hypoglycemia and Cardiovascular Risk: Is There a Major Link?. Diabetes Care 2016, 39, S205-S209, 10.2337/dcs15-3014.
85. Cushman, W.C.; Evans, G.W.; Byington, R.P.; Goff, D.C., Jr.; Grimm, R.H., Jr.; Cutler, J.A.; Simons-Morton, D.G.; Basile, J.N.; Corson, M.A.; Probstfield, J.L.; et al.et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1575–1585.
86. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355, 253–259.